Literature DB >> 16518845

Chromosome 16 tumor-suppressor genes in breast cancer.

Emad A Rakha1, Andrew R Green, Des G Powe, Rebecca Roylance, Ian O Ellis.   

Abstract

Loss of heterozygosity on the long arm of chromosome 16 is one of the most frequent genetic events in breast cancer, suggesting the presence of one or more classic tumor-suppressor genes (TSGs). It has been shown that E-cadherin is the TSG on 16q in lobular tumors. In a search for the target genes in more frequently occurring low-grade nonlobular tumors, the smallest region of overlap (SRO) in this area of the genome has been exhaustively searched for. However, the results have demonstrated remarkable complexity, and so a clear consensus on identification of the SRO boundaries has not been reached. Several genes in the vicinity of these SROs have been scrutinized as putative TSGs in breast cancer, but so far, none has fulfilled the criteria for target genes. This review discusses the complexity of the 16q region and the different approaches that have been, are being, and will be used to detect the target genes in this area. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2006        PMID: 16518845     DOI: 10.1002/gcc.20318

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  26 in total

1.  Suppression of survival signalling pathways by the phosphatase PHLPP.

Authors:  Audrey K O'Neill; Matthew J Niederst; Alexandra C Newton
Journal:  FEBS J       Date:  2012-03-16       Impact factor: 5.542

2.  Fine scale mapping of the breast cancer 16q12 locus.

Authors:  Miriam S Udler; Shahana Ahmed; Catherine S Healey; Kerstin Meyer; Jeffrey Struewing; Melanie Maranian; Erika M Kwon; Jinghui Zhang; Jonathan Tyrer; Eric Karlins; Radka Platte; Bolot Kalmyrzaev; Ed Dicks; Helen Field; Ana-Teresa Maia; Radhika Prathalingam; Andrew Teschendorff; Stewart McArthur; David R Doody; Robert Luben; Carlos Caldas; Leslie Bernstein; Laurence K Kolonel; Brian E Henderson; Anna H Wu; Loic Le Marchand; Giske Ursin; Michael F Press; Annika Lindblom; Sara Margolin; Chen-Yang Shen; Show-Lin Yang; Chia-Ni Hsiung; Daehee Kang; Keun-Young Yoo; Dong-Young Noh; Sei-Hyun Ahn; Kathleen E Malone; Christopher A Haiman; Paul D Pharoah; Bruce A J Ponder; Elaine A Ostrander; Douglas F Easton; Alison M Dunning
Journal:  Hum Mol Genet       Date:  2010-03-23       Impact factor: 6.150

3.  Depletion of Pleckstrin homology domain leucine-rich repeat protein phosphatases 1 and 2 by Bcr-Abl promotes chronic myelogenous leukemia cell proliferation through continuous phosphorylation of Akt isoforms.

Authors:  Isao Hirano; Satoki Nakamura; Daisuke Yokota; Takaaki Ono; Kazuyuki Shigeno; Shinya Fujisawa; Kaori Shinjo; Kazunori Ohnishi
Journal:  J Biol Chem       Date:  2009-03-04       Impact factor: 5.157

Review 4.  Turning off AKT: PHLPP as a drug target.

Authors:  Alexandra C Newton; Lloyd C Trotman
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014       Impact factor: 13.820

5.  CTCF haploinsufficiency destabilizes DNA methylation and predisposes to cancer.

Authors:  Christopher J Kemp; James M Moore; Russell Moser; Brady Bernard; Matt Teater; Leslie E Smith; Natalia A Rabaia; Kay E Gurley; Justin Guinney; Stephanie E Busch; Rita Shaknovich; Victor V Lobanenkov; Denny Liggitt; Ilya Shmulevich; Ari Melnick; Galina N Filippova
Journal:  Cell Rep       Date:  2014-05-01       Impact factor: 9.423

Review 6.  The impact of phosphatases on proliferative and survival signaling in cancer.

Authors:  Goutham Narla; Jaya Sangodkar; Christopher B Ryder
Journal:  Cell Mol Life Sci       Date:  2018-05-03       Impact factor: 9.261

7.  Comparison of genetic variation of breast cancer susceptibility genes in Chinese and German populations.

Authors:  David Barzan; Marlon R Veldwijk; Carsten Herskind; Yang Li; Bo Zhang; Elena Sperk; Wei-Dong Du; Xue-Jun Zhang; Frederik Wenz
Journal:  Eur J Hum Genet       Date:  2013-03-13       Impact factor: 4.246

8.  Patterns of CTCF and ZFHX3 Mutation and Associated Outcomes in Endometrial Cancer.

Authors:  Christopher J Walker; Mario A Miranda; Matthew J O'Hern; Joseph P McElroy; Kevin R Coombes; Ralf Bundschuh; David E Cohn; David G Mutch; Paul J Goodfellow
Journal:  J Natl Cancer Inst       Date:  2015-09-01       Impact factor: 13.506

9.  Common polymorphism in the phosphatase PHLPP2 results in reduced regulation of Akt and protein kinase C.

Authors:  John Brognard; Matthew Niederst; Gloria Reyes; Noel Warfel; Alexandra C Newton
Journal:  J Biol Chem       Date:  2009-03-26       Impact factor: 5.157

Review 10.  PHLiPPing the switch on Akt and protein kinase C signaling.

Authors:  John Brognard; Alexandra C Newton
Journal:  Trends Endocrinol Metab       Date:  2008-05-27       Impact factor: 12.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.